David Charles Klonoff

David Charles Klonoff's AcademicInfluence.com Rankings

Philosophy

#6040

World Rank

#9002

Historical Rank

Logic

#3232

World Rank

#4358

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David Charles Klonoff's Degrees

Doctorate Medicine University of California, San Francisco

Why Is David Charles Klonoff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Charles Klonoff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. (2008) (730)
Continuous glucose monitoring: roadmap for 21st century diabetes therapy. (2005) (663)
Threshold-based insulin-pump interruption for reduction of hypoglycemia. (2013) (584)
Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States (2020) (500)
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. (2021) (335)
An economic analysis of interventions for diabetes. (2000) (285)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. (2007) (279)
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). (2013) (241)
Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. (2011) (201)
Continuous glucose monitoring: A review of the technology and clinical use. (2017) (169)
COVID-19 Pandemic: Impact of Quarantine on Medical Students’ Mental Wellbeing and Learning Behaviors (2020) (164)
Stroke associated with cocaine use. (1989) (164)
Noninvasive Blood Glucose Monitoring (1997) (155)
Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital (2018) (150)
Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. (1991) (144)
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. (2020) (142)
Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. (2012) (129)
Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. (2021) (124)
The Surveillance Error Grid (2014) (119)
Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (2013) (117)
The Current Status of mHealth for Diabetes: Will it Be the Next Big Thing? (2013) (114)
Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID-19 (2020) (105)
Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors (2018) (100)
A review of continuous glucose monitoring technology. (2005) (98)
Consensus Report: The Current Role of Self-Monitoring of Blood Glucose in Non-Insulin-Treated Type 2 Diabetes (2011) (93)
Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity (2020) (88)
Consensus Statement on Inpatient Use of Continuous Glucose Monitoring (2017) (84)
The Artificial Pancreas: How Sweet Engineering Will Solve Bitter Problems (2007) (82)
Using Telemedicine to Improve Outcomes in Diabetes—An Emerging Technology (2009) (79)
Technical Aspects of the Parkes Error Grid (2013) (79)
Overview of Fluorescence Glucose Sensing: A Technology with a Bright Future (2012) (78)
A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes. (2014) (77)
Consensus Report of the Coalition for Clinical Research—Self-Monitoring of Blood Glucose (2008) (74)
Macroamylasemia and other immunoglobulin-complexed enzyme disorders. (1980) (72)
Continuous glucose monitoring systems - Current status and future perspectives of the flagship technologies in biosensor research. (2021) (70)
Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical? (2003) (69)
A Review of the Security of Insulin Pump Infusion Systems (2011) (64)
Fog Computing and Edge Computing Architectures for Processing Data From Diabetes Devices Connected to the Medical Internet of Things (2017) (62)
Evidence-based Mobile Medical Applications in Diabetes. (2016) (60)
Assisted Monitoring of Blood Glucose: Special Safety Needs for a New Paradigm in Testing Glucose (2010) (59)
Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic (2020) (59)
Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents (2008) (58)
Benefits and Limitations of Self-Monitoring of Blood Glucose (2007) (57)
Performance of Cleared Blood Glucose Monitors (2015) (56)
Point-of-Care Blood Glucose Meter Accuracy in the Hospital Setting (2014) (56)
Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: observational analysis of 27 countries (2020) (55)
Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline (2020) (55)
The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic, and hyperglycemic ranges. (2004) (54)
Chronic fatigue syndrome. (1992) (53)
Cybersecurity for Connected Diabetes Devices (2015) (52)
Effect of environmental pollutants PM-2.5, carbon monoxide, and ozone on the incidence and mortality of SARS-COV-2 infection in ten wildfire affected counties in California (2020) (49)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years* (2008) (47)
A randomized, multicentre trial evaluating the efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5) (2019) (47)
The Increasing Incidence of Diabetes in the 21st Century (2009) (47)
Smart Pens Will Improve Insulin Therapy (2018) (47)
Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis (2020) (47)
Noninvasive blood glucose monitoring. (1997) (45)
Wearable physiological systems and technologies for metabolic monitoring. (2018) (45)
Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial (2020) (44)
Drugs in the Pipeline for the Obesity Market (2008) (42)
Acute water intoxication as a complication of urine drug testing in the workplace. (1991) (41)
ENDOCRINOLOGY IN THE TIME OF COVID-19: Remodelling diabetes services and emerging innovation (2020) (40)
The Beneficial Effects of a Paleolithic Diet on Type 2 Diabetes and other Risk Factors for Cardiovascular Disease (2009) (39)
The Missing Element of Telemedicine for Diabetes: Decision Support Software (2009) (39)
Novel fungal FAD glucose dehydrogenase derived from Aspergillus niger for glucose enzyme sensor strips. (2017) (38)
Hypoglycemia Following Inadvertent and Factitious Sulfonylurea Overdosages (1995) (37)
Intensive Insulin Therapy in Critically Ill Hospitalized Patients: Making it Safe and Effective (2011) (36)
Afrezza Inhaled Insulin (2014) (36)
Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events (2015) (35)
Precision Medicine for Managing Diabetes (2015) (35)
The Expanding Role of Real-World Evidence Trials in Health Care Decision Making (2020) (35)
The Food and Drug Administration is Now Preparing to Establish Tighter Performance Requirements for Blood Glucose Monitors (2010) (34)
Behavioral Theory: The Missing Ingredient for Digital Health Tools to Change Behavior and Increase Adherence (2019) (34)
A Simplified Approach Using Rate of Change Arrows to Adjust Insulin With Real-Time Continuous Glucose Monitoring (2017) (34)
Computing the Surveillance Error Grid Analysis (2014) (34)
The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics (2020) (33)
Open Source Closed-Loop Insulin Delivery Systems: A Clash of Cultures or Merging of Diverse Approaches? (2018) (33)
The current status of bolus calculator decision-support software. (2012) (32)
Accuracy and preference assessment of prefilled insulin pen versus vial and syringe with diabetes patients, caregivers, and healthcare professionals (2013) (31)
Cryptosporidial and cytomegaloviral hepatitis and cholecystitis. (1987) (30)
Personalized Medicine for Diabetes (2008) (30)
Do Currently Available Blood Glucose Monitors Meet Regulatory Standards? 1-Day Public Meeting in Arlington, Virginia (2013) (27)
New Evidence Demonstrates That Self-Monitoring of Blood Glucose Does Not Improve Outcomes in Type 2 Diabetes—When This Practice is Not Applied Properly (2008) (26)
Overcoming Barriers to Adoption of Digital Health Tools for Diabetes (2018) (26)
Improved Outcomes from Diabetes Monitoring: The Benefits of Better Adherence, Therapy Adjustments, Patient Education, and Telemedicine Support (2012) (26)
Regulatory Controversies Surround Blood Glucose Monitoring Devices (2010) (26)
Diabetes and technology in 2030: a utopian or dystopian future? (2018) (26)
Replacements for Trans Fats—Will There Be an Oil Shortage? (2007) (25)
Progress in Development of an Artificial Pancreas (2009) (24)
The ASPIRE Study: Design and Methods of an In-Clinic Crossover Trial on the Efficacy of Automatic Insulin Pump Suspension in Exercise-Induced Hypoglycemia (2011) (24)
The Need for Clinical Accuracy Guidelines for Blood Glucose Monitors (2012) (23)
A Review of Continuous Glucose Monitoring Based Composite Metrics for Glycemic Control. (2020) (23)
Continuous Glucose Monitoring in the Hospital (2021) (23)
Development of the Diabetes Technology Society Blood Glucose Monitor System Surveillance Protocol (2015) (23)
Standardization process of continuous glucose monitoring: traceability and performance. (2020) (23)
Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes (2019) (22)
Development of a screen-printed carbon electrode based disposable enzyme sensor strip for the measurement of glycated albumin. (2017) (22)
Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference (2016) (22)
A Review of Blood Glucose Monitor Accuracy. (2018) (20)
Blood Gas Analyzer Accuracy of Glucose Measurements (2017) (20)
Insulin Pump Safety Meeting: Summary Report (2009) (20)
PRIDE Statement on the Need for a Moratorium on the CMS Plan to Cite Hospitals for Performing Point-of-Care Capillary Blood Glucose Monitoring on Critically Ill Patients. (2015) (20)
Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen (2019) (20)
Products for Monitoring Glucose Levels in the Human Body With Noninvasive Optical, Noninvasive Fluid Sampling, or Minimally Invasive Technologies (2021) (20)
Insulin Pump Occlusions: For Patients Who Have Been Around the (Infusion) Block (2017) (19)
Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens (2015) (19)
Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. (2014) (19)
Digital Diabetes Data and Artificial Intelligence: A Time for Humility Not Hubris (2018) (18)
Microdialysis of interstitial fluid for continuous glucose measurement. (2003) (17)
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. (2022) (17)
Consensus Statement on Use of Continuous Subcutaneous Insulin Infusion Therapy in the Hospital (2018) (17)
How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit (2021) (16)
Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery (2015) (16)
Telemedicine for Diabetes (2016) (16)
Now Is the Time for a Cybersecurity Standard for Connected Diabetes Devices (2016) (16)
The need for hypoglycemia detection and prevention in type 1 diabetes. (2001) (16)
Hemoglobinopathies and Hemoglobin A1c in Diabetes Mellitus (2020) (16)
The Diabetes Technology Society Green Diabetes Initiative (2020) (16)
Diabetes Technology & Therapeutics Evolves, Along with Our Knowledge About Alternate Site Testing (2002) (15)
Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice (2022) (15)
Cybersecurity Regulation of Wireless Devices for Performance and Assurance in the Age of “Medjacking” (2016) (15)
Accuracy and Injection Force of the Gla-300 Injection Device Compared With Other Commercialized Disposable Insulin Pens (2015) (15)
Twelve Modern Digital Technologies That are Transforming Decision Making for Diabetes and All Areas of Health Care (2013) (15)
Second Insulin Pump Safety Meeting: Summary Report (2010) (14)
Digital Health Interventions for Diabetes: Everything to Gain and Nothing to Lose (2019) (14)
New Opportunities for Digital Health to Thrive (2019) (14)
The Need for Performance Standards for Continuous Glucose Monitors (2007) (13)
Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. (2003) (13)
Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes (2017) (13)
Standards for Medical Device Cybersecurity in 2018 (2018) (13)
Round Table Discussion on Inpatient Use of Continuous Glucose Monitoring at the International Hospital Diabetes Meeting (2016) (13)
Hyperprolactinemia in a patient with a pituitary and an ovarian dermoid tumor: case report. (1990) (13)
Timely hospital glucose measurement: here today, gone tomorrow? (2014) (13)
Telemedicine for Diabetes After the COVID-19 Pandemic: We Can’t Put the Toothpaste Back in the Tube or Turn Back the Clock (2020) (13)
Electrochemical sensing system employing fructosamine 6‐kinase enables glycated albumin measurement requiring no proteolytic digestion (2016) (13)
The Importance of Continuous Glucose Monitoring in Diabetes (2000) (13)
A Review of Predictive Low Glucose Suspend and its Effectiveness in Preventing Nocturnal Hypoglycemia. (2019) (12)
The Benefits of Implanted Glucose Sensors (2007) (12)
Continuous Ketone Monitoring: A New Paradigm for Physiologic Monitoring (2021) (12)
Half-Unit Insulin Pens: Disease Management in Patients With Diabetes Who Are Sensitive to Insulin (2017) (12)
Improving the Safety of Blood Glucose Monitoring (2011) (12)
United Kingdom Prospective Diabetes Study Follow-Up Studies Establish a Legacy Effect of Therapy for Hyperglycemia but Not Hypertension (2008) (11)
Innovations in Technology for the Treatment of Diabetes: Clinical Development of the Artificial Pancreas (an Autonomous System) (2011) (11)
Engineered fungus derived FAD-dependent glucose dehydrogenase with acquired ability to utilize hexaammineruthenium(III) as an electron acceptor. (2018) (11)
Continuous Ketone Monitoring Consensus Report 2021 (2021) (11)
The thyroid nodule. (1982) (11)
Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device (2014) (11)
Supporting Good Intentions With Good Evidence: How to Increase the Benefits of Diabetes Social Media (2019) (11)
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes (2019) (11)
Mid-Infrared Spectroscopy for Noninvasive Blood Glucose Monitoring (1998) (11)
ASPIRE in-Home: Rationale, Design, and Methods of a Study to Evaluate the Safety and Efficacy of Automatic Insulin Suspension for Nocturnal Hypoglycemia (2013) (11)
A Milestone in Point of Care Capillary Blood Glucose Monitoring of Critically Ill Hospitalized Patients (2018) (11)
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia (2021) (10)
Quality Control of Insulins and Biosimilar Insulins (2016) (10)
Digital Diabetes Communication (2016) (10)
Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis (2020) (10)
The pen is mightier than the needle (and syringe). (2001) (10)
ADAG Study Group Data Links A1C Levels with Empirically Measured Blood Glucose Values - New Treatment Guidelines Will Now be Needed (2014) (10)
Analysis: Serum Fructosamine as a Screening Test for Type 2 Diabetes (2000) (10)
Advances in Insulin Pump Infusion Sets Symposium Report (2021) (10)
New Wearable Computers Move Ahead (2014) (10)
Technology to Treat Hyperglycemia in Trauma (2007) (9)
The First Recall of a Diabetes Device Because of Cybersecurity Risks (2019) (9)
Subcutaneous continuous glucose monitoring in severe burn patients. (2007) (9)
Effect of Environmental Pollutants PM2.5, CO, NO2, and O3 on the Incidence and Mortality of SARS-CoV-2 Infection in Five Regions of the USA (2021) (9)
Hospital Diabetes Meeting 2020 (2020) (9)
Human monkeypox outbreak: global prevalence and biological, epidemiological and clinical characteristics - observational analysis between 1970-2022. (2022) (8)
Current, emerging, and future trends in metabolic monitoring. (2002) (8)
Pharmacoadherence: An Opportunity for Digital Health to Inform the Third Dimension of Pharmacotherapy for Diabetes (2020) (8)
Telemedicine for Diabetes (2016) (8)
Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapies (2017) (8)
SMBG Out of Control (2013) (8)
Digital Diabetes Congress 2019 (2019) (8)
The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record (2021) (7)
User and Healthcare Professional Perspectives on Do-It-Yourself Artificial Pancreas Systems: A Need for Guidelines (2020) (7)
An Opportunity to Increase the Benefit of CGM Usage: The Need to Train the Patients Adequately (2019) (7)
Clinical Evaluation of a Rapid A1c Test (a1cnow) for Home Use (2006) (7)
Insulin Pumps and Continuous Glucose Monitoring Made Easy (2015) (7)
Serum fructosamine as a screening test for type 2 diabetes. (2000) (7)
The Need for Precision Medicine to be Applied to Diabetes (2020) (7)
The YSI 2300 Analyzer Replacement Meeting Report (2020) (6)
The Diabetes Technology Society Green Declaration (2021) (6)
Designing an Artificial Pancreas System to Be Compatible with other Medical Devices (2008) (6)
Blood Glucose Meter Market: This World is Undergoing Drastic Changes (2013) (6)
A Sweetened Beverage Tax is Needed to Combat the Obesity Epidemic as Well as Related Absenteeism and Presenteeism (2009) (6)
Incretin therapy for type 2 diabetes mellitus (2010) (6)
The Launch of the iCoDE Standard Project (2022) (6)
Time synching or time sinking? (2005) (6)
Digital Connectivity: The Sixth Vital Sign (2021) (6)
Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing (2020) (6)
Postmarket Surveillance of Blood Glucose Monitor Systems Is Needed for Safety of Subjects and Accurate Determination of Effectiveness in Clinical Trials of Diabetes Drugs and Devices (2019) (6)
Association of hyperinsulinemia with chlorpropamide toxicity. (1988) (6)
Green Diabetes Summit 2021 (2021) (6)
Trends in FDA Regulation of Software to Control Insulin Dosing (2015) (6)
Diabetes Technology Society Report on the FDA Digital Health Software Precertification Program Meeting (2018) (5)
Editorial: Welcome to Diabetes Technology & Therapeutics (1999) (5)
Functional Evaluation of the Reusable JuniorSTAR® Half-Unit Insulin Pen (2015) (5)
Finding Real Value From Digital Diabetes Health: Is Digital Health Dead or in Need of Resuscitation? (2018) (5)
Evaluation of the JuniorSTAR® Half-unit Insulin Pen in Young People with Type 1 Diabetes - User Perspectives. (2013) (5)
The Need for a Glycemia Modeling Comparison Workshop to Facilitate Development of an Artificial Pancreas (2010) (5)
Hospital Diabetes: Why Quality of Care Matters to Both Patients and Hospitals (2011) (5)
Smart Sensors for Maintaining Physiologic Homeostasis (2011) (4)
Glutamic Acid Decarboxylase Therapy for Recent-Onset Type 1 Diabetes: Are We at the End or the Beginning of Finding a Cure? (2009) (4)
Automated Insulin Dosing Systems or Automated Insulin Delivery Systems? It is Time for Consistency (2021) (4)
The Personalized Medicine for Diabetes Meeting Summary Report (2009) (4)
Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come? (2022) (4)
Technology for portable measurement of blood lactate. (2003) (4)
European trends in diabetes technology--continuous glucose measurements and computerized information-processing tools. (2002) (4)
Inhaled insulin. (1999) (4)
Propionibacterium acnes pneumonia in a patient with lymphoma (2005) (4)
The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now? (2019) (4)
New Technologies for Glucose Monitoring and Insulin Administration (2016) (4)
Semaglutide single‐dose pen‐injector: Post hoc analysis of summative usability testing for weight management (2021) (4)
Digital Diabetes Congress 2017 (2017) (4)
Excess Mortality in COVID-19-Positive Versus COVID-19-Negative Inpatients With Diabetes: A Nationwide Study (2021) (4)
Insulin Pump System Security (2010) (4)
Hospital Diabetes Meeting (2014) (4)
Improved Insulin Absorption by Means of Standardized Injection Site Modulation Results in a Safer and More Efficient Prandial Insulin TreatmentA Review of the Existing Clinical Data (2014) (4)
Now Is the Time for a Security and Safety Standard for Consumer Smartphones Controlling Diabetes Devices (2017) (4)
Continuous Glucose Monitoring Technology Delivers Detailed Diabetes Data (2006) (3)
The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward (2019) (3)
The Need for a Privacy Standard for Medical Devices That Transmit Protected Health Information Used in the Precision Medicine Initiative for Diabetes and Other Diseases (2017) (3)
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial (2020) (3)
User experiences with second-generation 32-gauge × 4 mm vs. thinner comparator pen needles: prospective randomized trial (2020) (3)
A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages. (2003) (3)
Predictors of Time-to-Repeat Point-of-Care Glucose Following Hypoglycemic Events in Hospitalized Patients (2020) (3)
The Need for Sharps Waste Disposal Guidelines for Commercial Airports (2021) (3)
New labeling and use changes for Rezulin. (1999) (3)
Barriers and Solutions to a Recently Noted Failure of Diabetes Care Outcomes to Improve From 2005 to 2016 in the United States (2020) (3)
Spending for Diabetes Drugs is Increasing in the United States (2008) (3)
Diagnosing diabetes mellitus from smartphone-based vascular signals (2020) (3)
111-LB: Hepatic Insulin Delivery to Minimize Hypoglycemic Events in Persons with Type 1 Diabetes: The OPTI-1 Study (2020) (3)
The Coronavirus 2019 Pandemic and Diabetes: An International Perspective (2020) (3)
Continuous glucose monitoring study does not demonstrate benefit in children and adolescents. (2009) (3)
iCoDE June 22, 2022 Steering Committee Meeting Summary Report (2022) (2)
Fibroblast Growth Factor: Will This Hormone Be the Hemoglobin A1c for Managing Phosphorus Balance in Chronic Kidney Disease? (2010) (2)
Editorial: Diabetes Technology & Therapeutics Enters the 21st Century (2000) (2)
FDA Clinical Chemistry and Clinical Toxicology Devices Panel. (1999) (2)
Elderly Patients With Diabetes: Special Aspects to Consider (2019) (2)
Diabetes Technology and Waste: A Complex Story (2021) (2)
Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications and Adverse Effects of JYNNEOS and ACAM2000 Monkeypox Vaccines (2022) (2)
Dirlotapide, a U.S. Food and Drug Administration-Approved First-in-Class Obesity Drug for Dogs—Will Humans Be Next? (2007) (2)
Non-invasive Fourier Transformed Infrared Spectroscopy for the Measurement of Submucosal Tissue Glucose Concentration — Application of Chalcogenide Optical Fiber System (1998) (2)
Is Digital Health for Diabetes in an Investment Bubble? (2020) (2)
Antioxidant-Induced Pseudohyperglycemia Due to Interference of Measurements by Blood Glucose Monitors (2021) (2)
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. (2021) (2)
Telehealth Fatigue: Is It Real? What Should Be Done? (2022) (2)
Using ChatGPT to Predict the Future of Diabetes Technology (2023) (2)
Technology to Treat Hyperglycemia in Trauma Patients (2007) (2)
Chronic fatigue syndrome and neurally mediated hypotension. (1996) (2)
The promise of optical sensing strategies for glucose. (1999) (2)
Business and Economics of Diabetes (2008) (2)
A Gut-Centric Model of Metabolic Homeostasis (2021) (2)
Input of Patients for New Diabetes Technology Products (2021) (1)
Bariatric Surgery for Obese Adolescents (2007) (1)
Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System. (2022) (1)
Smart insulin pens and devices to track insulin doses (2020) (1)
Noninvasive Glucose Monitoring: In God We Trust—All Others Bring Data (2021) (1)
Editorial: New Products and New Technologies for Diabetes (1999) (1)
News from the FDA (2000) (1)
Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics (2018) (1)
An Interview about Telemedicine with John Oxendine, Georgia Insurance and Fire Commissioner, and Paula Guy, R.N., Chief Executive Officer of the Georgia Partnership for Telehealth (2009) (1)
Pyruvate therapy for severe hypoglycemia. (2005) (1)
Freedom of Speech and Science: Can Companies Force Us to Withdraw Data They Don't Like? (2013) (1)
FDA approves new Glucose Monitoring System. (1999) (1)
An Economic Analysis of Interv e n t i o n s for Diabetes (2000) (1)
The link between diabetes, military metabolic monitoring, and NASA. (2003) (1)
New products and new technologies for diabetes. (1999) (1)
Performance of Cleared Blood Glucose Monitor Systems (2018) (1)
Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics (2018) (1)
Journal of Diabetes Science and Technology: A Success Story! (2020) (1)
Digital Diabetes Congress 2018 (2018) (1)
Artificial Intelligence for Predicting and Diagnosing Complications of Diabetes (2022) (1)
Editorial: New Home Blood Monitoring Technology Improves Blood Glucose Control in Diabetes (2000) (1)
What Do Your Fingernails Say About You? Can They Indicate That You Have Diabetes? (2015) (1)
Meeting Report: The Fourth Artificial Pancreas Workshop: Testing and Adoption of Current and Emerging Technologies (2017) (1)
1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial (2020) (1)
Successful Performance of Laboratory Investigations with Blood Glucose Meters Employing a Dynamic Electrochemistry-Based Correction Algorithm Is Dependent on Careful Sample Handling. (2016) (1)
Digital Health Approaches for Improved Population Health Outcomes: Time for a Disease Vulnerability Matrix for Individuals and Communities? (2021) (1)
Bioartificial Pancreas – Slow Progress but Much Promise: Report of the JDRF/NASA/NIDDK/NCRR Workshop (2002) (1)
A New Digital Point-of-Care Tool With Advanced Blood Glucose Measuring Technology. (2022) (1)
The FDA Pilot Accreditation Scheme for Conformity: Will It Pertain to Cybersecurity of Diabetes Devices? (2021) (1)
Clinical chemistry and clinical toxicology devices advisory panel recommendation on Glucowatch. (2000) (1)
Reduced hypoglycaemia using liver‐targeted insulin in individuals with type 1 diabetes (2022) (1)
Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589 (2019) (1)
Environmental Pollutants PM2.5, PM10, Nitrogen Dioxide (NO2), and Ozone (O3) Association with the Incidence of Monkeypox Cases in European Countries (2023) (1)
Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial (2021) (1)
Diabetes Technology Meeting 2020 (2021) (1)
Update on Measuring Ketones. (2023) (0)
In-hospital Stabilisation of Blood-sugar Control using an Insulin Balanced Infusion System (Admetsys):: Clinical results from FDA-approved Clinical Studies in 43 Diabetes Patients (2016) (0)
Analytical performance of SMBG systems (2020) (0)
Inappropriate drug prescribing. (1995) (0)
Urine Drug Testing, Water Intoxication, and Anticholinergic Medication-Reply (1991) (0)
II. Critical care closed loop glucose control system: Advancing the development. (2018) (0)
User- and Health Care Provider–Reported Outcomes for a Wearable Bolus Insulin Delivery Patch (2018) (0)
Diabetes Technology Meeting 2022. (2023) (0)
Special funding boosts type 1 diabetes research. (2001) (0)
Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study (2023) (0)
Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study (2023) (0)
Improved pharmacokinetic and pharmacodynamic profile of insulin analogs using InsuPatch , a local heating device Running Title : Local heating device and insulin action (2014) (0)
1084-P: Divergent Hypoglycemic Effects of Hepatic Directed Prandial Insulin: A 6-Month Study in Type 1 Diabetes Mellitus (T1DM) (2019) (0)
Glucose data-mining study inconclusive. (2015) (0)
Continuous subcutaneous infusion versus multiple daily injections of insulin for type 1 diabetes in pregnancy (2023) (0)
The New Food and Drug Administration Center for Devices and Radiological Health Engineering and Physics Laboratory and Methods for Testing Software That Controls Infusion Pumps (2007) (0)
Diabetes and Hyperglycemia are Risk Factors for Adverse Outcomes in COVID-19 (2021) (0)
Expressing the sense of the Senate to raise the awareness of the devastating impact of diabetes and to support increased funds for diabetes research. (1999) (0)
Barriers and Solutions to Trends and Disparities in Glycemic Control and Severe Hyperglycemia Among US Adults With Diabetes Using Insulin From 1988 to 2020 (2023) (0)
Relationship between daytime vs nighttime continuous glucose monitoring metrics with A1C in Adults with Type 1 Diabetes. (2022) (0)
Painful Diabetic Neuropathy: The Need for New Approaches. (2022) (0)
Trimetazidine Blocks Lipid Oxidation—Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis? (2022) (0)
The UCSF Diabetes Symposium: Research Breakthroughs in Diabetes. (1999) (0)
Diabetes Technology Meeting 2021 (2022) (0)
Reply Letter - Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. (2021) (0)
Evidence and Diabetes Technology: A Catch-22? (2023) (0)
The “Catalyst to Better Diabetes Care Act of 2007” (2008) (0)
The Need to Change Regulatory Evaluation of Hypoglycemia in Trials of Diabetes Treatments (2019) (0)
NIAID spearheads collaborative network for clinical research on immune tolerance. (2000) (0)
Impact of green space environment on the prevalence of diabetes mellitus in european countries (2022) (0)
Regarding a successful treatment with artificial pancreas for a patient who attempted suicide using a high‐dose insulin s.c. injection (2020) (0)
Corrigendum to: Continuous Glucose Monitoring: An Endocrine Society Clinical Practice Guideline. (2021) (0)
The Impact of ISO 22870 on the Quality and Competence of Continuous Glucose Monitoring in the Hospital Setting (2011) (0)
Emerging Technologies in Rapid-Acting Prandial Insulin (2014) (0)
FDA approves new glucose test for adult diabetics. (2001) (0)
Human Research Program (HRP) Exploration Medical Capability (ExMC) Standing Review Panel (SRP) (2009) (0)
78-LB: Association between Daytime vs. Nighttime Mean Glucose and Time-in-Range with A1C in Adults with Type 1 Diabetes (2022) (0)
A Roadmap to an Equitable Digital Diabetes Ecosystem. (2022) (0)
617-P: Association between Change in Time-in-Range and A1C in Basal Insulin-Treated People with Type 2 Diabetes (2021) (0)
Journal of Diabetes Science and Technology and the Diabetes Technology Community (2007) (0)
618-P: Association between Time-in-Range and A1C in Basal Insulin-Treated People with Type 2 Diabetes (2021) (0)
Retained Diabetes Devices-A Literature Review. (2022) (0)
Treating an Unconscious Patient With Diabetes Wearing a Device Attached to Their Body (2022) (0)
Spinal Cord Stimulation for Painful Diabetic Neuropathy. (2022) (0)
Artificial Pancreas (1989) (0)
The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes. (2002) (0)
Technologies for Metabolic Monitoring (TMM): a new research initiative. (2002) (0)
Diabetes Prevention Program meets recruitment goals. (1999) (0)
Benefits of Conformity Assessment for Cybersecurity Standards of Diabetes Devices and Other Medical Devices (2021) (0)
Promising Technological Frontiers in Monitoring and Treatment (2010) (0)
The Fourth Annual Clinical Diabetes Technology Meeting (2008) (0)
I. Critical care closed loop glucose control system: Preliminary studies. (2018) (0)
Allen M. Spiegel, M.D., named Director of NIDDK. (2000) (0)
Second Annual Diabetes Technology Meeting (2000) (0)
Lipohypertrophy and Insulin. An Old Dog that Needs New Tricks. (2023) (0)
Clinical dehydration scale appears valid, but its impact on clinical outcomes is not clear (2009) (0)
A Newly FDA-Cleared Benchtop Glucose Analyzer Heralds the Dawn of the Post–YSI 2300 Era (2022) (0)
Use of a Diabetes Self-Management App in Combination with a 4mm Pen Needle and its Impact on Glycemic Variability and Patient Reported Outcomes in People with Type 2 Diabetes Using Basal-Bolus Insulin Therapy (Preprint) (2021) (0)
Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589 (2018) (0)
The Availability of Sharps Disposal Bins: A Survey of Airports in California (2021) (0)
Optimizing Basal-Bolus Therapy in T2D—A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch vs. an Insulin Pen (2018) (0)
An adaptive drug infusion system. (2004) (0)
Summary of Seventh Annual Diabetes Technology Meeting October 25-27, 2007 San Francisco, California. (2008) (0)
CHRONIC FATIGUE SYNDROME AND NEURALLY MEDIATED HYPOTENSION. AUTHORS' REPLY (1996) (0)
Hospital Diabetes Meeting 2022 (2022) (0)
Session 3 : Defining the Population of Target Users Within the Diabetes Global Village Moderator : (2017) (0)
blood flow during local heating Nitric oxide and neurally mediated regulation of skin (2015) (0)
Real-World Evidence Supports Higher Prevalence of Heart Failure Among Persons With Type 1 and Type 2 Diabetes Compared With the General Population (2023) (0)
Machine Learning Glycemic Predictions for the Hospital Using Electronic Health Record Data (2022) (0)
Summary of Sixth Annual Diabetes Technology Meeting, November 2-4, 2006, Atlanta, Georgia. (2007) (0)
Breakthrough technology for in-hospital glucose monitoring. (2022) (0)
Improving Care for People Living With Dementia and Diabetes: Applying the Human-Centered Design Process to Continuous Glucose Monitoring. (2022) (0)
Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia (2021) (0)
Regarding "Detection of Hypoglycemia and Hyperglycemia Using Noninvasive Wearable Sensors: ECG and Accelerometry". (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Charles Klonoff?

David Charles Klonoff is affiliated with the following schools:

University of California, San Francisco